Go to the list of all blogs
Sergey Savastiouk's Avatar
published in Blogs
Oct 29, 2026
TickeronGET DAILY SIGNALS
NovoCure (NVCR) Delivers Record Q3 Revenue and Positive EBITDA Despite Optune Pax Setback

NovoCure (NVCR) Delivers Record Q3 Revenue and Positive EBITDA Despite Optune Pax Setback

Key Takeaways

  • Third-quarter 2026 net revenue climbed 16% year over year to a record $193.4 million, exceeding consensus estimates near $182 million.
  • Net loss narrowed sharply to $10.4 million, or $0.09 per share, beating the analyst consensus loss of roughly $0.21 to $0.24 per share.
  • Adjusted EBITDA turned positive at $15.7 million, a key profitability inflection point versus a $3.0 million loss a year earlier.
  • Management raised full-year 2026 revenue guidance to $736 million–$743 million and adjusted EBITDA guidance to $24 million–$34 million.
  • The Optune Pax pancreatic cancer launch stalled, with active patients slipping to 276 from 285 in the prior quarter, clouding the growth story despite the beat.

Why This Quarter Matters for NovoCure

NovoCure's third-quarter report matters because it sits at a pivotal moment for the oncology company's transition from a single-product, glioblastoma-focused business into a multi-indication growth platform. The company has posted three consecutive quarters of beats and guidance raises, and this print confirmed its core brain cancer franchise, Optune Gio, is reaccelerating while its newer lung and pancreatic cancer devices begin to contribute. Crucially, the quarter marked the company's return to positive adjusted EBITDA, a milestone investors have been watching closely as proof that NovoCure can scale toward profitability. At the same time, the report exposed competitive pressure in pancreatic cancer, where a newly approved oral therapy is challenging the launch of Optune Pax. How management navigates that headwind will shape the stock's narrative into 2027.

Reported Results

For the third quarter ended September 30, 2026, NovoCure reported net revenue of $193.4 million, up 16% from $167.2 million a year earlier and above the roughly $182 million consensus. The top line included a $4.4 million one-time benefit from higher insurance claim approval rates in the U.S. and Germany. Net loss narrowed to $10.4 million, or $0.09 per share, compared with a $37.3 million loss, or $0.33 per share, in the prior-year period. Gross margin improved to 77% from 73%. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.

Adjusted EBITDA swung to a positive $15.7 million from a $3.0 million loss a year ago. Active patients on Tumor Treating Fields (TTFields) therapy rose 19% to a record 5,260. Optune Gio, for glioblastoma, reached 4,729 active patients, up 11%, while the lung cancer device Optune Lua grew to 255 active patients. Optune Pax, for pancreatic cancer, generated $3.7 million but saw active patients dip to 276 from 285.

Management raised 2026 guidance, now projecting revenue of $736 million–$743 million (up from $710 million–$725 million) and adjusted EBITDA of $24 million–$34 million. The implied fourth-quarter revenue range of $185 million–$192 million reflects normalization of one-time benefits.

Market Reaction and Investor Sentiment

Despite a clean beat on both revenue and earnings plus a third consecutive guidance raise, NVCR shares fell roughly 5% to 9% on the report, according to market data. The sell-off centered on management's candid comments that the Optune Pax launch has hit a wall in the U.S., where the recently approved oral drug daraxonrasib from Revolution Medicines has captured oncologists' attention and "significantly limited" NovoCure's access to physician practices. That concern overshadowed otherwise strong results: record revenue, an improving gross margin, and a return to positive adjusted EBITDA. Investors appeared to interpret the pancreatic cancer setback as a risk to the company's newest growth leg, even as the core brain cancer business and the Japanese Optune Lua launch performed well. The reaction highlights how much of the stock's near-term narrative now depends on execution in newer indications rather than the established GBM franchise.

Forward Outlook and Key Factors to Monitor

Several catalysts and risks will define NovoCure's story in the coming months. First, the U.S. Food and Drug Administration is expected to issue a decision by year-end on Optune Mya, the company's premarket approval application for treating brain metastases from non-small cell lung cancer. A favorable ruling could support a potential launch in early 2027 and would represent the next major expansion opportunity.

Second, investors should track whether Optune Pax regains momentum. Management pointed to upcoming updates to the National Comprehensive Cancer Network treatment guidelines and new clinical trials pairing TTFields with other pancreatic cancer agents, but the near-term launch trajectory remains uncertain given the competitive environment.

Third, completion of enrollment in the phase III KEYNOTE-D58 trial, which is evaluating TTFields plus immunotherapy in newly diagnosed glioblastoma, is expected by year-end and could reinforce the company's core franchise. Finally, watch the pace of adjusted EBITDA progression, as management cautioned that profitability may not improve in a straight line due to fourth-quarter launch preparation spending. Overall, the company's balance sheet, with about $463.5 million in cash and short-term investments, provides a runway to pursue these initiatives.

Exploring Tickeron’s AI Tools for Ongoing Research

I often turn to Tickeron’s AI Screener when reviewing names like NVCR alongside peers. It lets me quickly filter by fundamentals, technical patterns, and AI signals to spot comparable opportunities or confirm relative strength. The tool has helped me build a more disciplined watchlist without spending hours on manual screens, and I find it especially useful around earnings seasons when multiple data points need cross-checking.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: NVCR

Contributor

Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.


NVCR in -4.04% downward trend, declining for three consecutive days on November 19, 2026

Moving lower for three straight days is viewed as a bearish sign. Keep an eye on this stock for future declines. Considering data from situations where NVCR declined for three days, in 311 of 351 cases, the price declined further within the following month. The odds of a continued downward trend are 89%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on October 29, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on NVCR as a result. In 70 of 81 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 86%.

The Moving Average Convergence Divergence Histogram (MACD) for NVCR turned negative on October 29, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 47 similar instances when the indicator turned negative. In 41 of the 47 cases the stock turned lower in the days that followed. This puts the odds of success at 87%.

The 50-day moving average for NVCR moved below the 200-day moving average on November 16, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.

The Aroon Indicator for NVCR entered a downward trend on November 20, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Bullish Trend Analysis

The RSI Indicator shows that the ticker has stayed in the oversold zone for 4 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an Uptrend is expected.

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 8 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

Following a +10.60% 3-day Advance, the price is estimated to grow further. Considering data from situations where NVCR advanced for three days, in 205 of 273 cases, the price rose further within the following month. The odds of a continued upward trend are 75%.

NVCR may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 27 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is 80 (best 1 - 100 worst), indicating slightly worse than average price growth. NVCR’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Seasonality Score of 85 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Valuation Rating of 97 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.574) is normal, around the industry mean (4.142). P/E Ratio (-10.215) is within average values for comparable stocks, (3.291). Projected Growth (PEG Ratio) (40.950) is also within normal values, averaging (11.253). Dividend Yield (0.000) settles around the average of (0.011) among similar stocks. P/S Ratio (2.634) is also within normal values, averaging (40.124).

The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. NVCR’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

Notable companies

The most notable companies in this group are Abbott Laboratories (NYSE:ABT), Medtronic plc (NYSE:MDT), Boston Scientific Corp (NYSE:BSX), Edwards Lifesciences Corp (NYSE:EW).

Industry description

The medical/nursing services includes companies that provide medical-related services such as ambulance services, dialysis centers, respiratory therapy, blood testing and rehabilitation services. DaVita Inc., Chemed Corporation and Guardant Health, Inc. are examples of companies in this industry.

Market Cap

The average market capitalization across the Medical/Nursing Services Industry is 6.17B. The market cap for tickers in the group ranges from 837 to 190.22B. ABT holds the highest valuation in this group at 190.22B. The lowest valued company is DHAI at 837.

High and low price notable news

The average weekly price growth across all stocks in the Medical/Nursing Services Industry was -11%. For the same Industry, the average monthly price growth was -15%, and the average quarterly price growth was -18%. MXCT experienced the highest price growth at 15%, while CODX experienced the biggest fall at -50%.

Volume

The average weekly volume growth across all stocks in the Medical/Nursing Services Industry was -35%. For the same stocks of the Industry, the average monthly volume growth was -2% and the average quarterly volume growth was -21%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 48
P/E Growth Rating: 50
Price Growth Rating: 64
SMR Rating: 89
Profit Risk Rating: 94
Seasonality Score: 16 (-100 ... +100)
1-on-1 3
View a ticker or compare two or three
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a commercial-stage oncology company

Industry MedicalNursingServices

Industry
Medical Specialties
Address
Grenville Street
Phone
+44 1534756700
Employees
1605
Web
https://www.novocure.com
Interact to see
Advertisement
Alphabet Inc. (GOOG) , the parent of Google, YouTube, and Google Cloud, is a common stock, not an exchange-traded fund. The central target of $400 is the arithmetic mean of current analyst price targets, which span a wide band from roughly $300 to $500, with the broad average near $397.
AAPL has shown stronger relative performance in recent weeks, holding near record highs while many artificial intelligence (AI)-focused tech stocks sold off. MSFT has lagged the market and now trades below its 50-day moving average amid concerns over heavy AI infrastructure spending.
Bending Spoons reported third-quarter 2026 revenue of $780.22 million, up 125.1% year over year and above the roughly $745.86 million consensus estimate. Earnings per share (EPS) came in at $0.42, beating the $0.26 consensus estimate by $0.16.
GOOG declined roughly 20% over the past 30 days, falling from about $331 to around $264 per share. The sell-off was triggered by Alphabet's third-quarter 2026 report, which revealed slowing Search advertising growth and an earnings miss.
Intel Corporation has delivered dramatically stronger relative price momentum over the past year, while SPY offers broad, diversified market exposure with far lower single-stock volatility. INTC's rally has been driven by a strategic turnaround under new leadership, backed by multi-billion-dollar investments from Nvidia, SoftBank, and the U.S. government.
NovoCure (NVCR) Delivers Record Q3 Revenue and Positive EBITDA Despite Optune Pax Setback